Literature DB >> 20967517

Coexistence of chronic myeloid leukemia and pulmonary plasmacytoma mimicking primary lung cancer.

Hee Jin Kim1, Moon Jin Kim, Min Jeong Lee, Jong-Hwa Ahn, Ho-Su Kim, In-Suk Kim, Jong Sil Lee, Gyeong-Won Lee.   

Abstract

A 61-year-old man was diagnosed with the simultaneous occurrence of chronic myeloid leukemia (CML) and infiltrative intrathoracic plasmacytoma, radiologically mimicking bronchogenic carcinoma. Following the administration of imatinib mesylate (IM; 400 mg/day), both hematologic and partial cytogenetic remission of CML were achieved. However, the pulmonary plasmacytoma was persistently aggravated. High-dose dexamethasone was added to the IM therapy because the patient refused radiotherapy to control the aggravated pulmonary plasmacytoma. Finally, he died due to pneumonia and multi-organ failure during concurrent administration of IM and high-dose dexamethasone.

Entities:  

Mesh:

Year:  2010        PMID: 20967517     DOI: 10.1007/s12185-010-0705-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  11 in total

1.  Multiple myeloma preceding the development of chronic myelogenous leukemia.

Authors:  M Nitta; K Tsuboi; S Yamashita; M Kato; Y Hayami; S Harada; H Komatsu; S Iida; S Banno; A Wakita; R Ueda
Journal:  Int J Hematol       Date:  1999-04       Impact factor: 2.490

2.  Simultaneous occurrence of chronic myeloid leukemia and multiple myeloma: evaluation by FISH analysis and in vitro expansion of bone marrow cells.

Authors:  J D Schwarzmeier; M Shehata; J Ackermann; M Hilgarth; H Kaufmann; J Drach
Journal:  Leukemia       Date:  2003-07       Impact factor: 11.528

3.  Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.

Authors:  Vassilia Garipidou; Sofia Vakalopoulou; Konstantinos Tziomalos
Journal:  Oncologist       Date:  2005 Jun-Jul

4.  Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.

Authors:  A Galanopoulos; S I Papadhimitriou; E Kritikou-Griva; M Georgiakaki; N I Anagnostopoulos
Journal:  Ann Hematol       Date:  2008-08-26       Impact factor: 3.673

Review 5.  Uncommon case of chronic myeloid leukemia with multiple myeloma.

Authors:  Masaru Ide; Nobuo Kuwahara; Eijo Matsuishi; Shinya Kimura; Hisashi Gondo
Journal:  Int J Hematol       Date:  2010-03-30       Impact factor: 2.490

6.  Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months.

Authors:  Michalis Michael; Marios Antoniades; Elena Lemesiou; Nicandros Papaminas; Freiderikh Melanthiou
Journal:  Oncologist       Date:  2009-12-02

7.  Multiple myeloma superimposed on chronic myelocytic leukemia.

Authors:  C Derghazarian; N B Whittemore
Journal:  Can Med Assoc J       Date:  1974-05-04       Impact factor: 8.262

8.  Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents.

Authors:  Atanasio Pandiella; Xonia Carvajal-Vergara; Soraya Tabera; Gema Mateo; Norma Gutiérrez; Jesús F San Miguel
Journal:  Br J Haematol       Date:  2003-12       Impact factor: 6.998

Review 9.  Multiple myeloma and chronic myelogenous leukemia--a case report with literature review.

Authors:  P J Klenn; B H Hyun; Y H Lee; W Y Zheng
Journal:  Yonsei Med J       Date:  1993-09       Impact factor: 2.759

10.  Development of multiple myeloma in a patient with gastrointestinal stromal tumor treated with imatinib mesylate: a case report.

Authors:  D Tzilves; A Gatopoulou; K Zervas; E Katodritou; F Patakiouta; A Tarpagos; I Katsos
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.